Brightgene Bio-Medical Technology Co. Ltd. has divulged new gastric inhibitory polypeptide receptor (GIPR), glucagon receptor (GCGR) and glucagon-like peptide 1 receptor (GLP-1R) agonists potentially useful for the treatment of neurodegeneration, bone, metabolic and cardiovascular disorders.
Ethyreal Bio Inc. has developed ETHY-001, a half-life-extended monoclonal antibody targeting thyroid-stimulating hormone receptor (TSHR) designed to prevent the production of pathogenic autoantibodies (TSAbs) to treat Graves’ hyperthyroidism and thyroid eye disease (TED).
Prime Medicine Inc. has obtained clearance from the New Zealand authority, Medsafe, for the company’s clinical trial application for PM-577a, an investigational Prime Editor for Wilson’s disease.
At the recent Endocrine Society meeting in Chicago, Kalohexis Inc. presented preclinical efficacy data on 710GO, an oral dual MC3R/MC4R agonist, in obese nonhuman primates (NHPs).
Constantiam Biosciences Inc. and Cincinnati Children’s have established a strategic collaboration, through an exclusive option for future licensing rights, to advance first-in-class small-molecule treatments for neuronopathic Gaucher disease (types 2 and 3).
Researchers from Rivus Pharmaceuticals Inc. presented preclinical efficacy data on RV‑202, a novel oral mitochondrial uncoupler with activity attributed to adenine nucleotide translocase (ANT) activation, in models of obesity.
Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist developed using the company’s proprietary technology platform for the treatment of life-threatening hypoglycemic episodes associated with post-bariatric hypoglycemia (PBH).
Beam Therapeutics Inc. has obtained IND clearance from the FDA for BEAM-304 for the treatment of phenylketonuria (PKU). BEAM-304 is a liver-targeting lipid-nanoparticle (LNP) formulation of base editing reagents designed to correct mutations in the phenylalanine hydroxylase (PAH) gene that cause PKU.
Chinese peptide therapeutics developer Shaanxi Micot Pharmaceutical Technology Co. Ltd. is seeking up to HK$1.22 billion (US$155 million) in a Hong Kong IPO to advance its lead phase III chronic kidney disease candidate, MT-1013, and next-generation obesity therapies.
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges are well known, such as loss of muscle mass loss, compliance and accessibility. With more treatments moving through the pipeline, innovation and technology will be key to supporting long-term use, delegates heard at the HLTH Europe conference in Amsterdam on June 17.
RSS
